Sterling Capital Management LLC Sells 3,525 Shares of Biogen Inc. $BIIB

Sterling Capital Management LLC lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 40.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,136 shares of the biotechnology company’s stock after selling 3,525 shares during the quarter. Sterling Capital Management LLC’s holdings in Biogen were worth $942,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Rothschild Investment LLC boosted its position in shares of Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Itau Unibanco Holding S.A. raised its stake in Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after buying an additional 66 shares during the period. Advisory Services Network LLC lifted its holdings in Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares in the last quarter. Davis Investment Partners LLC grew its stake in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the period. Finally, Optas LLC increased its holdings in shares of Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 73 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on BIIB shares. Guggenheim boosted their price objective on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Needham & Company LLC raised their target price on shares of Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler reiterated an “overweight” rating and issued a $225.00 price target (up from $214.00) on shares of Biogen in a report on Friday, May 15th. HC Wainwright reissued a “buy” rating on shares of Biogen in a research report on Thursday, May 14th. Finally, Sanford C. Bernstein dropped their price objective on shares of Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $217.41.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham raised its price target on Biogen to $256 and reiterated a Buy rating, citing stronger-than-expected Spinraza HD momentum and progress across the company’s pipeline. Biogen: Key Takeaways From Needham’s Meeting With Top Management
• Positive Sentiment: Biogen said it will showcase new Alzheimer’s disease data at AAIC 2026, including Phase 2 CELIA results for diranersen and additional lecanemab analyses, which could reinforce confidence in one of its key growth areas. Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026
• Positive Sentiment: Biogen was highlighted alongside other biotech leaders hitting new 52-week highs, reflecting broader sector strength and momentum in the stock. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Neutral Sentiment: Zacks added Biogen-related ticker BBIB to its Strong Sell list, but this appears to be a separate ticker and not a direct negative on Biogen Inc. itself. New Strong Sell Stocks for June 30th
• Negative Sentiment: One report said Biogen is trimming Apellis-related R&D spending and pausing or ending investment in most legacy programs after its acquisition, which may raise integration and capital-allocation concerns. Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
• Negative Sentiment: Biogen was also mentioned in a class action settlement notice, which could keep some legal overhang on the shares, though the announcement itself is not a new operational setback. Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

Biogen Trading Down 0.3%

NASDAQ BIIB opened at $216.06 on Wednesday. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $219.72. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock’s 50 day moving average price is $194.96 and its two-hundred day moving average price is $186.27. The stock has a market capitalization of $31.90 billion, a price-to-earnings ratio of 23.18 and a beta of 0.20.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same period last year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 13.95 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.